国际眼科纵览

• 综述 • 上一篇    下一篇

血管内皮生长因子在增生性玻璃体视网膜病变中的作用

卢亚楠 张东昌 原莉莉   

  1. 030001 山西医科大学(卢亚楠系在读硕士研究生);山西省眼科医院(张东昌、原莉莉)
  • 收稿日期:2015-12-31 出版日期:2016-06-25 发布日期:2016-06-26
  • 通讯作者: 张东昌,Email: zhangdongchanghome@163.com

Role of vascular endothelial growth factor in proliferative vitreoretinopathy

LU Ya-nan 1,ZHANG Dong-chang 2, YUAN Li-li 2.   

  1. 1. Shanxi Medical University, 2. Eye Hospital of Shanxi Province,Taiyuan 030001, China
  • Received:2015-12-31 Online:2016-06-25 Published:2016-06-26
  • Contact: ZHANG Dong-chang, Email: zhangdongchanghome@163.com

摘要:

增生性玻璃体视网膜病变(proliferative vitreoretinopathy,PVR)发病机制尚未完全明确。大量研究证实血管内皮生长因子(vascular endothelial growth factor,VEGF)在PVR视网膜前增生膜组织及玻璃体中表达增高;在动物模型中,抗VEGF治疗可有效防止PVR的发生发展。VEGF促进PVR发展的机制可能在于VEGF竞争性地抑制血小板源性生长因子(platelet-derived growth factor,PDGF)结合血小板源性生长因子受体α(platelet-derived growth factor receptor α,PDGFR-α),从而促进非血小板源性生长因子(non-PDGFs)活化PDGFR-α,激活PI3K/Akt信号通路,减少p53基因的表达。

Abstract:

The pathogenesis of proliferative vitreoretinopathy (PVR) is not totally clear. Vascular endothelial growth factor (VEGF) was demonstrated to be increased in vitreous and epiretinal membranes of patients with PVR and animal PVR models. In animal PVR models, anti-VEGF therapy could effectively prevent the development of PVR. The mechanism of VEGF promoting the development of PVR may be that VEGF competes with platelet-derived growth factor (PDGF) for binding to platelet-derived growth factor receptor α (PDGFR-α). VEGF therefore increases the pool of monomeric PDGFR-α available to be indirectly activated by growth factors outside PDGF (non-PDGFs), stimulating signaling pathways such as PI3K/Akt, which reduces the level of p53.